Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
November 07 2022 - 5:10AM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-258301
Prospectus Supplement
(To Prospectus dated
August 6, 2021)
This prospectus supplement supplements and amends the prospectus dated August 6, 2021 (the
Prospectus), as supplemented and amended by that certain prospectus supplement dated November 22, 2021 covering the offering, issuance and sale of up to a maximum aggregate offering price of $90,000,000 (the Maximum Offering
Price) of our common stock that may be issued and sold under a sales agreement with B. Riley Securities, Inc., BTIG, LLC and H.C. Wainwright & Co., LLC (the ATM Facility).
Effective as of November 7, 2022, we have reduced the Maximum Offering Price to $70,000,000. As of the date of this prospectus
supplement, 9,692,632 shares have been sold under the ATM Facility.
You should read this prospectus supplement, together with additional
information described under the headings Information Incorporated by Reference and Where You Can Find Additional Information in the Prospectus carefully before you invest in our securities.
Investing in our securities involves a high degree of risk. Before making any investment in our securities, you should consider carefully the
risks and uncertainties described in the section entitled Risk Factors beginning on page 2 of the Prospectus.
The
date of this prospectus supplement is November 7, 2022.
Biora Therapeutics (NASDAQ:PROG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biora Therapeutics (NASDAQ:PROG)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Biora Therapeutics Inc (NASDAQ): 0 recent articles
More Biora Therapeutics, Inc. News Articles